Status:
COMPLETED
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
Lead Sponsor:
Asahi Kasei Pharma Corporation
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study
Eligibility Criteria
Inclusion
- Diagnosis of RA (class I to III)
- Stable dose of methotrexate (at least 12 weeks)
Exclusion
- Pregnant or breastfeeding
- Abnormal screening laboratory test values considered to be clinically significant
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00902369
Start Date
May 1 2009
End Date
July 1 2010
Last Update
July 25 2016
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Hlučín, Czechia
2
Prague, Czechia
3
Uherské Hradiště, Czechia
4
Frankfurt am Main, Hesse, Germany